OSR Health, Inc. (OSRH) Form 8-K — Oct 16, 2026
OSR Health amended its VXM01 license agreement with BCM Europe AG to let the company convert up to $15 million of its equity purchase option into a convertible note financing. The notes would be issued in four $3.75 million tranches with fixed conversion prices of roughly $2.00, $3.00, $4.00 and $5.00 per share, with no reset provision. The amendment was driven by a Nasdaq delisting determination issued August 19, 2026, which the parties call a material development affecting settlement of the original equity option. BCME has identified a purchaser and must deliver a binding purchase commitment with or before OSRH's election notice.
Key figures
- Debt Amount
- 15000000
- Tranche size
- 3750000
- Conversion prices
- ["$2.00","$3.00","$4.00","$5.00"]
- Number of tranches
- 4
- Warrant exercise price
- 11.5
- Closing window business days
- 20
- Delisting determination date
- 2026-08-19
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.